{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/breastfeeding-problems/prescribing-information/fluconazole/","result":{"pageContext":{"chapter":{"id":"6cd5a8b3-d7ea-577c-919e-0e1050c25ada","slug":"fluconazole","fullItemName":"Fluconazole","depth":2,"htmlHeader":"<!-- begin field 18a9c8de-3d6f-4609-967c-5f2f37a31a82 --><h2>Fluconazole</h2><!-- end field 18a9c8de-3d6f-4609-967c-5f2f37a31a82 -->","summary":"","htmlStringContent":"<!-- begin item 1783422e-bdba-478c-b602-4f6f20094ed2 --><!-- begin field 1489d7f9-a790-4b39-973e-4b591fff3177 --><ul><li>Fluconazole is present in breast milk, but the amount is probably too small to be harmful.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>]</p><!-- end field 1489d7f9-a790-4b39-973e-4b591fff3177 --><!-- end item 1783422e-bdba-478c-b602-4f6f20094ed2 -->","topic":{"id":"4d56065b-4316-58f6-aae8-5f7154ca6148","topicId":"c8e357d0-0bb7-413a-bc3b-caf10d9584ce","topicName":"Breastfeeding problems","slug":"breastfeeding-problems","lastRevised":"Last revised in May 2017","chapters":[{"id":"f183a7e4-fb16-5c51-8e82-8040a8fd2543","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6c3771ea-501b-5f7e-8d4f-d1142d882322","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2e3dcd26-e84a-59d0-8323-03f0685cd6a1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"acf6ae76-da75-5e22-97ae-25b268d9bd76","slug":"changes","fullItemName":"Changes"},{"id":"2a520e88-6970-5c6c-81ab-6f85a403dbdf","slug":"update","fullItemName":"Update"}]},{"id":"e7b1ffd6-53e0-5248-9ef9-c3d9335bcaf8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"afea2557-003c-5cab-9d6a-1843fad84de1","slug":"goals","fullItemName":"Goals"},{"id":"84c298f8-a5b4-5f98-b2ff-15a45fcb4f26","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f21fc58c-8a25-5b15-a6bc-e737e68b787c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d379cce3-06f5-500f-8022-947483b96061","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5e716806-4895-5480-a837-2377a13b6842","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3da2e4cd-2a4d-5ed8-9747-eb0ca53b146d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5ea41579-133a-58f2-84ff-408513f6ec84","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"31ec7fd5-e27e-52f3-b236-31efd054a396","slug":"definition","fullItemName":"Definition"},{"id":"2a023940-e489-5105-8632-13827c70ea6a","slug":"causes-of-breast-pain","fullItemName":"Causes of breast pain"},{"id":"9c0c022a-236d-5b78-8edb-8e7db2f37e29","slug":"causes-of-nipple-pain","fullItemName":"Causes of nipple pain"},{"id":"223571de-a0b7-5f12-bec5-8a80ace52548","slug":"causes-of-low-milk-supply","fullItemName":"Causes of low milk supply"},{"id":"83d5346e-7f4a-522d-9773-4a6dd40c604e","slug":"causes-of-milk-oversupply","fullItemName":"Causes of milk oversupply"}]},{"id":"82725ef1-b602-5cb0-9269-61529b6c2b02","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b1de0ed8-0423-5ead-aa5d-5cff64d0c321","slug":"assessment","fullItemName":"Assessment"},{"id":"472503aa-271b-514d-b4de-814e67a7a751","slug":"diagnosis-of-breast-pain","fullItemName":"Diagnosis of breast pain"},{"id":"4cc8cba0-c1f6-58b0-a13b-89abe37d504a","slug":"diagnosis-of-nipple-pain","fullItemName":"Diagnosis of nipple pain"},{"id":"f5afa158-bf6a-5287-91d4-87b5c001b13f","slug":"diagnosis-of-low-milk-supply","fullItemName":"Diagnosis of low milk supply"},{"id":"f8136aa4-95ef-5fdd-be27-e87dd0245585","slug":"diagnosis-of-milk-oversupply","fullItemName":"Diagnosis of milk oversupply"}]},{"id":"ca97794b-54f8-5bef-80ca-c5524975c2ad","fullItemName":"Management","slug":"management","subChapters":[{"id":"f9f8c0db-f1cc-552d-94f3-3bf6fc0028c5","slug":"breastfeeding-problems-management","fullItemName":"Scenario: Breastfeeding problems - management"}]},{"id":"1cfd7617-7b51-58ed-ab16-896215c43349","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8bef9e53-ca1d-5b61-8b12-8b014e6bd3ec","slug":"paracetamol","fullItemName":"Paracetamol"},{"id":"1eaac104-bf91-5b86-afd3-c5d5437e4e93","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"4727ad63-3ff6-54b1-867f-894d33d550d2","slug":"erythromycin-clarithromycin","fullItemName":"Erythromycin and clarithromycin"},{"id":"6cd5a8b3-d7ea-577c-919e-0e1050c25ada","slug":"fluconazole","fullItemName":"Fluconazole"},{"id":"138c913a-c62a-5e10-9697-9f868ae99220","slug":"topical-fusidic-acid","fullItemName":"Topical fusidic acid"},{"id":"46d7af18-cc56-5707-8fcf-ae4b2bed882f","slug":"topical-miconazole","fullItemName":"Topical miconazole"}]},{"id":"c0e2db87-1126-5519-94ac-7719d6dc0798","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"409d7d9d-3f69-54b8-aa5c-eea89923ea9e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d3d4c30-3488-5158-acfe-2d12bdb10359","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49e75f6f-5655-58b1-8933-8fa4c3819b8a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d5b6c020-e109-5b11-aefd-70df672efa79","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"87720b05-a3b7-5a75-a206-9bfc4d167e76","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cb469aba-1f15-5f6e-bfb6-fa073612150f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"416d347c-3b3f-530d-8323-4bb4de52b3fe","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1cfd7617-7b51-58ed-ab16-896215c43349","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"60df49c3-5c33-5e40-b780-ad172f4be3b8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e709db9f-ca69-42b0-8b67-a6f6015b779c --><h3>Contraindications and cautions</h3><!-- end field e709db9f-ca69-42b0-8b67-a6f6015b779c -->","summary":"","htmlStringContent":"<!-- begin item fa00e595-36a0-43a5-ac2b-a6f6015b75da --><!-- begin field 7543ec6f-c733-4401-8646-a6f6015b779c --><p><strong>Do not prescribe o</strong><strong>ral fluconazole to women:</strong></p><ul><li>Who are pregnant.</li><li>With acute porphyria.</li></ul><p><strong>Prescribe oral fluconazole with caution to women:</strong></p><ul><li>At risk of QT interval prolongation — such as cardiomyopathy, sinus bradycardia, arrhythmias, hypokalaemia, hypomagnesaemia, hypocalcaemia, and those taking other drugs known to cause QT interval prolongation (such as tricyclic antidepressants, antipsychotics, or antiarrhythmics).</li><li>With hepatic impairment or taking concurrent hepatotoxic drugs, due to the risk of hepatic necrosis — discontinue if symptoms or signs of hepatic disease develop (such as severe upper abdominal pain or jaundice).  </li><li>With renal impairment — if the estimated glomerular filtration rate (eGFR) is less than 50mL/min/1.73m<sup>2</sup>, use the usual initial dose then halve any subsequent doses.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>]</p><!-- end field 7543ec6f-c733-4401-8646-a6f6015b779c --><!-- end item fa00e595-36a0-43a5-ac2b-a6f6015b75da -->","subChapters":[]},{"id":"4191d343-8439-5370-9cc1-3b5094937136","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 28fdff2c-bef6-48f4-a3f2-a6f6015b9364 --><h3>Adverse effects</h3><!-- end field 28fdff2c-bef6-48f4-a3f2-a6f6015b9364 -->","summary":"","htmlStringContent":"<!-- begin item 64f9fc75-d0e8-404d-85b5-a6f6015b9248 --><!-- begin field ea87c927-5313-47f7-bfa7-a6f6015b9364 --><p><strong>Adverse effects </strong><strong>of oral fluconazole include:</strong></p><ul><li><strong>Common or very common</strong><ul><li>Abdominal discomfort, diarrhoea, nausea, and flatulence.</li><li>Headache and rash.</li></ul></li><li><strong>Uncommon</strong><ul><li>Alopecia, adrenal insufficiency, dizziness.</li><li>Vomiting, dyspepsia, and taste disturbance.</li><li>Hepatic disorders.</li><li>Hyperlipidaemia.</li><li>Seizures, pruritus, anaphylaxis and hypersensitivity reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>]</p><!-- end field ea87c927-5313-47f7-bfa7-a6f6015b9364 --><!-- end item 64f9fc75-d0e8-404d-85b5-a6f6015b9248 -->","subChapters":[]},{"id":"89e96f83-b809-56ee-be76-73ae419c752a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 40338efc-e028-4c62-9248-a6f6015ba57b --><h3>Drug interactions</h3><!-- end field 40338efc-e028-4c62-9248-a6f6015ba57b -->","summary":"","htmlStringContent":"<!-- begin item a3832388-bc17-4dfc-9aaa-a6f6015ba491 --><!-- begin field ed9134a3-94f4-4ece-833f-a6f6015ba57b --><p>Fluconazole inhibits cytochrome P450 enzymes CYP3A4, 2C9, and 2C19, and may therefore increase the levels of many drugs that are metabolized by these enzymes. In addition, drugs that inhibit or induce these enzymes may increase or decrease the plasma concentrations of fluconazole. In general, fluconazole drug interactions relate to multiple-dose treatment.</p><ul><li><strong>The following drugs should be avoided:</strong><ul><li>Amiodarone, astemizole, pimozide, quinidine — concurrent use with fluconazole may result in increased plasma concentrations of these drugs, leading to QT prolongation and rare occurrences of Torsade de Pointes.</li><li>Cisapride — there have been reports of cardiac events (including Torsades de pointes) during concurrent treatment with fluconazole.</li><li>Ergot alkaloids (such as ergotamine and methysergide) — there is an increased risk of ergotism.</li><li>Erythromycin — concurrent use with fluconazole has the potential to increase the risk of cardiotoxicity due to prolonged QT interval, such as Torsades de pointes and sudden cardiac death.</li><li>Quetiapine — fluconazole possibly increases plasma concentrations of quetiapine.</li><li>Reboxetine  — the manufacturer advises that fluconazole should not be given with reboxetine.</li><li>Terfenadine — serious cardiac arrhythmias secondary to prolongation of the QT interval have been reported.</li></ul></li><li><strong>Fluconazole may increase plasma concentrations of the following drugs — concurrent use should be monitored, and dose adjustments may be indicated:</strong><ul><li>Aminophylline and theophylline.</li><li>Ciclosporin.</li><li>Diazepam (risk of prolonged sedation).</li><li>Fentanyl.</li><li>Midazolam (risk of prolonged sedation).</li><li>Phenytoin.</li><li>Rifabutin (increased risk of uveitis).</li><li>Statins — the risk of myopathy and rhabdomyolysis increases when fluconazole is given with statins metabolized through CYP3A4 (atorvastatin and simvastatin), or through CYP2C9 (fluvastatin).<ul><li>If concurrent treatment is necessary, monitor for symptoms of myopathy and rhabdomyolysis, and monitor creatine kinase.</li><li>Discontinue the statin if a marked increase in creatine kinase is observed or if myopathy or rhabdomyolysis is diagnosed or suspected.</li></ul></li><li>Sulfonylureas.</li><li>Tacrolimus.</li><li>Warfarin (and indanedione anticoagulants) — fluconazole enhances the anticoagulant effect.<ul><li>Monitor the international normalized ratio (INR) closely, and adjust the anticoagulant dose accordingly.  </li></ul></li><li>Zidovudine (increased risk of toxicity).</li></ul></li><li><strong>Other possible drug interactions of fluconazole include:</strong><ul><li>Clopidogrel — fluconazole possibly reduces the antiplatelet effect of clopidogrel.</li><li>Rifampicin — metabolism of fluconazole accelerated by rifampicin (reduced plasma concentration).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>]</p><!-- end field ed9134a3-94f4-4ece-833f-a6f6015ba57b --><!-- end item a3832388-bc17-4dfc-9aaa-a6f6015ba491 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}